Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nepal pilot tests early birth control Shot's impact on breastfeeding

NCT ID NCT06816901

Knowledge-focused Sponsor: University of California, San Diego Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This pilot study in Nepal looked at whether it is possible to run a larger trial on starting the birth control shot DMPA within 48 hours after giving birth. 40 new mothers who wanted DMPA and planned to breastfeed exclusively were enrolled. The main goal was to see if researchers could recruit enough participants, while also tracking how long it took for breast milk to come in and how many women kept using DMPA.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Depo medroxyprogesterone acetate (DMPA) injection
What this could lead to
If successful, this pilot could pave the way for a larger study that clarifies whether starting DMPA soon after birth is safe for breastfeeding and infant growth.
What could go wrong
This is a very small pilot study (40 people) focused on feasibility, not on proving safety or effectiveness. Results may not apply broadly, and the larger trial may not happen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

40 people

The number who actually took part.

Started

Mar 2025

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Currently live in Nepal * Had a vaginal or cesarean delivery of a singleton full-term infant within the past 48 hours * Not yet undergone lactogenesis * Desire to use DMPA as a method of postpartum contraception Exclusion Criteria: * Desire a repeat pregnancy in less than 6 months * Do not intend to exclusively feed infant own human milk for 6 months * Do not have access to a telephone * Any medical contraindication to DMPA * Any contraindication to human milk feeding for their infant * History of breast surgery (augmentation or reduction) * Infant with a major congenital anomaly (will be excluded due to unique challenges with feeding in these populations)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Depot medroxyprogesterone acetate are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Breast Feeding lactation disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Depot medroxyprogesterone acetate DMPA Lactation Postpartum contraception

Contacts and locations

Locations

  • Provincial Hospital Janakpur of Dhanusha district

    Janakpur Dham, Dhanusha District, Nepal

More trials for these conditions

Other studies related to the condition(s) this trial covers.